ArticlePatient preference and adherence2026
Beyond the Prescription: Hydroxycarbamide Utilization and Adherence Among Persons Living with Sickle Cell Disease in Rural Ghana.
Article in Patient preference and adherence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the utilization and adherence to hydroxycarbamide therapy among sickle cell disease (SCD) patients in a rural Ghanaian setting, and predictors of adherence. Patients and Methods: We conducted a cross-sectional study among 100 SCD patients receiving care at a rural health facility in Ghana. Data were collected using a structured questionnaire administered to adult patients and caregivers of paediatric patients. Descriptive statistics and multivariable logistic regression were used to assess hydroxyurea utilisation, adherence, and associated factors. Results: The study population was predominantly paediatric, with caregivers completing questionnaires for most participants. More than half of the respondents (56%) had use hydroxyurea for over 2 years. While 80% reported always taking the drug, the majority admitted to missing at least one dose in the preceding month. The most reported barriers were forgetfulness (50%) and financial constraints (44.6%). Although gender and educational level were associated with adherence in unadjusted analyses, these factors were not independent predictors in the multivariable logistic regression model. Conclusion: Hydroxyurea utilization in this rural setting is encouraging and reflects the positive impact of national policies such as the "Ahodwo Program". However, adherence challenges persist. This is primarily driven by behavioral and financial barriers than demographic factors. Optimising hydroxyurea use will require targeted interventions, including patient and caregiver education and financial risk protection mechanisms that build on the existing national programs. From a policy perspective, these findings support strengthening caregiver-centred adherence interventions. Future studies should prioritise age-stratified, longitudinal designs to better characterise adherence patterns in adults and children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.